elf Beauty Inc header image

elf Beauty Inc

ELF

Equity

ISIN null / Valor 33775016

New York Stock Exchange, Inc (2025-11-21)
USD 70.05+2.38%

elf Beauty Inc
UMushroom community rating:

star star star star star
4.73 3 votes No rating yet
NegativeNeutralPositive

About company

Elf Beauty Inc is a cosmetics company that offers affordable and high-quality beauty products.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (16.11.2025):

elf Beauty Inc’s Q4 Fiscal 2025 financial results demonstrate robust performance with continued net sales growth for the 25th consecutive quarter. The company delivered solid top-line and profitability improvements driven by strength in retailer and e-commerce channels, while also achieving higher gross margins and disciplined SG&A expenses. Notably, elf Beauty Inc reinforced its market position by announcing an acquisition agreement for the fast-growing beauty brand, rhode, as part of its strategic expansion efforts.

Q4 Sales and Profitability

For the three months ended March 31, 2025, elf Beauty Inc’s net sales increased 4% to $332.6 million, and gross margin improved by approximately 50 basis points to 71%. GAAP net income for Q4 reached $28.3 million, with adjusted net income rising to $45.2 million, underscoring the company’s operational efficiency and cost management.

Expense Management and Earnings

During Q4 Fiscal 2025, SG&A expenses were reduced by $17.4 million to $192.7 million, representing 58% of net sales, while adjusted SG&A was contained at $173.3 million (52% of net sales). These expense management efforts contributed to adjusted diluted earnings per share of $0.78 and an impressive 99% year-over-year improvement in adjusted EBITDA, which reached $81.4 million or 24% of net sales.

Strategic Expansion and Future Outlook

In addition to strong Q4 performance, elf Beauty Inc announced its definitive agreement to acquire rhode, a fast-growing beauty brand founded by Hailey Bieber. This strategic move, along with planned discussions during its webcast on May 28, 2025, highlights the company’s ongoing growth initiatives and commitment to maintaining its market leadership in Fiscal 2025.

Summarized from source with an LLMView Source

Key figures

-42.8%1Y
28.7%3Y
225%5Y

Performance

69.8%1Y
60.0%3Y
52.6%5Y

Volatility

Market cap

4178 M

Market cap (USD)

Daily traded volume (Shares)

2,120,797

Daily traded volume (Shares)

1 day high/low

128.91 / 124

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.73

3 votes
Performance:
starstarstarstarstar
4.45
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
4.45
Josh Ellis
United Kingdom, 20 Oct 2025
star star star star star
good buy
Laura Bischofberger
Switzerland, 26 Mar 2025
star star star star star
eher neuer an der Börse und ein gutes Upside Potenzial.
Lou Charlotte Wehrli
Switzerland, 24 Mar 2025
star star star star star
Spannende Aktie und noch spannendere Produkte. Goldman Sachs stuft elf Beauty als undervalued ein. Bin gespannt, wie sich das weiterhin entwickelt.

EQUITIES OF THE SAME SECTOR

Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%CHF 96.58
National Healthcare Corp
National Healthcare Corp National Healthcare Corp Valor: 836282
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.42%USD 130.44
Maternus-Kliniken AG
Maternus-Kliniken AG Maternus-Kliniken AG Valor: 335800
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.94%EUR 1.05
Dyne Therapeutics Inc
Dyne Therapeutics Inc Dyne Therapeutics Inc Valor: 56806425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
5.27%USD 21.18
Boiron SA
Boiron SA Boiron SA Valor: 487646
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%EUR 26.60
COSMO Pharmaceuticals N.V.
COSMO Pharmaceuticals N.V. COSMO Pharmaceuticals N.V. Valor: 32590356
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%CHF 67.10
Astrana Health Inc
Astrana Health Inc Astrana Health Inc Valor: 28041888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.62%USD 22.50
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA SCHOTT Pharma AG & Co. KGaA Valor: 128964250
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 18.44
Coloplast A/S
Coloplast A/S Coloplast A/S Valor: 20259063
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.55%DKK 580.20
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.21%USD 5.03